Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways

Current Topics in Medicinal Chemistry

Volumn 11, Issue 12, 2011, Pages 1571-1590

  Zhong, Haizhen ^a   Phillip Bowen, J ^b,c  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^c Joint School of Nanoscience and Nanoengineering   (United States)

Author keywords

AEE788; And ponatinib; Axitinib; BIBF1120; Brivanib; Cediranib; Dovitinib; E7080; Linifanib; Motesanib; Regorafenib; SU5416; Tandutinib; Telatinib; Tivozanib; Vandetanib; Vatalanib; XL880

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AXITINIB; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FORETINIB; GEFITINIB; IMATINIB; INTEDANIB; IXABEPILONE; LAPATINIB; LENVATINIB; LINIFANIB; LXEMPRA; MOTESANIB; NILOTINIB; PANITUMUMAB; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SORAFENIB; SUNITINIB; TANDUTINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VATALANIB;

ADVANCED CANCER; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLEEDING; BLOOD VESSEL PERMEABILITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; DESQUAMATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EPITHELIUM TUMOR; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IC 50; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; NONHUMAN; OVARY ADENOCARCINOMA; PERIPHERAL NEUROPATHY; PROSTATE CANCER; RASH; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TUMOR CELL; TUMOR VOLUME; UTERINE CERVIX CANCER;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 79959986387     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611795860924     Document Type: Review

References (140)

1. Senger, D. R.; Galli, S. J.; Dvorak, A. M.; Perruzzi, C. A.; Harvey, V. S.; Dvorak, H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 1983, 219, 983-985.
2. Yarden, Y.; Ullrich, A. Growth factor receptor tyrosine kinases. Annu. Rev. Biochem. 1988, 57, 443-478.
3. Zhong, H.; Bowen, J. P. Molecular design and clinical development of VEGFR kinase inhibitors. Curr. Top. Med. Chem., 2007, 7, 1379-1393.
4. Murakami, M.; Iwai, S.; Hiratsuka, S.; Yamauchi, M.; Nakamura, K.; Iwakura, Y.; Shibuya, M. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood, 2006, 108, 1849-1856.
5. Nakamura, K.; Taguchi, E.; Miura, T.; Yamamoto, A.; Takahashi, K.; Bichat, F.; Guilbaud, N.; Hasegawa, K.; Kubo, K.; Fujiwara, Y.; Suzuki, R.; Kubo, K.; Shibuya, M.; Isoe, T. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res., 2006, 66, 9134-9142.
6. Suzuki, S.; Dobashi, Y.; Sakurai, H.; Nishikawa, K.; Hanawa, M.; Ooi, A. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer 2005, 103, 1265-1273.
7. Los, M.; Roodhart, J. M. L.; Voest, E. E. Target practice: lessons from phase iii trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist, 2007, 12, 443-450.
8. Gordon, M. S.; Mendelson, D. S.; Kato, G. Tumor angiogenesis and novel antiangiogenic strategies. Int. J. Cancer, 2010, 126, 1777-1787.
9. Jain, R. K. Normalization of tumor Vasculature: An emerging concept in antiangiogenic therapy. Science, 2005, 307, 58-62.
10. Douillard, J. Y.; Siena, S.; Cassidy, J.; Tabernero, J.; Burkes, R.; Barugel, M.; Humblet, Y.; Bodoky, G.; Cunningham, D.; Jassem, J.; Rivera, F.; Kocákova, I.; Ruff, P.; Błasińska-Morawiec, M.; Šmakal, M.; Canon, J. L.; Rother, M.; Oliner, K. S.; Wolf, M.; Gansert, J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol., 2010, 28, 4697-4705.
11. Bokemeyer, C.; Bondarenko, I.; Makhson, A.; Hartmann, J. T.; Aparicio, J.; de Braud, F.; Donea, S.; Ludwig, H.; Schuch, G.; Stroh, C.; Loos, A. H.; Zubel, A.; Koralewski, P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol., 2009, 27, 663-671.
12. Grothey, A. EGFR antibodies in colorectal cancer: Where do they belong? J. Clin. Oncol., 2010, 28, 4668-4670.
13. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350, 2335-2342.
14. Thatcher, N.; Chang, A.; Parikh, P.; Rodrigues, P. J.; Ciuleanu, T.; von Pawel, J.; Thongprasert, S.; Tan, E. H.; Pemberton, K.; Archer, V.; Carroll, K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366, 1527-1537.
15. Cho, B. C.; Im, C. K.; Park, M. S.; Kim, S. K.; Chang, J.; Park, J. P.; Choi, H. J.; Kim, Y. J.; Shin, S. J.; Sohn, J. H.; Kim, H.; Kim, J. H. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J. Clin. Oncol., 2007, 25, 2528-2533.
16. Murray, S.; Dahabreh, I. J.; Linardou, H.; Manoloukos, M.; Bafaloukos, D.; Kosmidis, P. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: An analytical database. J. Thorac. Oncol., 2008, 3, 832-839.
17. Yun, C.-H.; Boggon, T. J.; Li, Y.; Woo, M. S.; Greulich, H.; Meyerson, M.; Eck, M. J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell, 2007, 11, 217-227.
18. Toyooka, S.; Kiura, K. EGFR mutation and response of lung cancer to gefitinib. N. Engl. J. Med., 2005, 352, 2136-2136.
19. Zhong, H.; Tran, L. M.; Stang, J. L. Induced-fit docking studies of the active and inactive states of protein tyrosine kinases. J. Mol. Graph. Model., 2009, 28, 336-346.
20. Sharma, S. V.; Bell, D. W.; Settleman, J.; Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer, 2007, 7, 169-181.
21. Yoshida, T.; Zhang, G.; Haura, E. B. Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer. Biochem. Pharmacol., 2010, 80, 613-623.
22. Druker, B. J.; Lydon, N. B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest., 2000, 105, 3-7.
23. Demetri, G. D.; von Mehren, M.; Blanke, C.D.; Van den Abbeele, A. D.; Eisenberg, B.; Roberts, P. J.; Heinrich, M. C.; Tuveson, D. A.; Singer, S.; Janicek, M.; Fletcher, J. A.; Silverman, S. G.; Silberman, S. L.; Capdeville, R.; Kiese, B.; Peng, B.; Dimitrijevic, S.; Druker, B. J.; Corless, C.; Fletcher, C. D.; Joensuu, H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med., 2002, 347, 472-480.
24. Shah, N. P.; Tran, C.; Lee, F. Y.; Chen, P.; Norris, D.; Sawyers, C. L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 2004, 305, 399-401.
25. Tokarski, J. S.; Newitt, J.; Chang, C. Y. J.; Cheng, J. D.; Wittekind, M.; Kiefer, S. E.; Kish, K.; Lee, F. Y. F.; Borzillerri, R.; Lombardo, L. J.; Xie, D.; Zhang, Y.; Klei, H. E. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res., 2006, 66, 5790-5797.
26. Cowan-Jacob, S. W.; Fendrich, G.; Floersheimer, A.; Furet, P.; Liebetanz, J.; Rummel, G.; Rheinberger, P.; Centeleghe, M.; Fabbro, D.; Manley, P. W. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukemia. Acta Crystallogr., Sect. D, 2007, 63, 80-93.
27. Lombardo, L. J.; Lee, F. Y.; Chen, P.; Norris, D.; Barrish, J. C.; Behnia, K.; Castaneda, S.; Cornelius, L. A. M.; Das, J.; Doweyko, A. M.; Fairchild, C.; Hunt, J. T.; Inigo, I.; Johnston, K.; Kamath, A.; Kan, D.; Klei, H.; Marathe, P.; Pang, S.; Peterson, R.; Pitt, S.; Schieven, G. L.; Schmidt, R. J.; Tokarski, J.; Wen, M. L.; Wityak, J.; Borzilleri, R. M. Discovery of N-(2-Chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual src/abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem., 2004, 47, 6658-6661.
28. Nam, S.; Kim, D.; Cheng, J.Q.; Zhang, S.; Lee, J. H.; Buettner1, R.; Mirosevich1, J.; Lee, F. Y.; Jove1, R. Action of the Src family kinase inhibitor, dasatinib (BMC-354825), on human prostate cancer cells. Cancer Res., 2005, 65, 9185-9189.
29. Fiskus, W.; Pranpat, M.; Balasis, M.; Bali, P.; Estrella, V.; Kumaraswamy, S.; Rao, R.; Rocha, K.; Herger, B.; Lee, F.; Richon, V.; Bhalla, K. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylateresistant chronic myelogenous leukemia cells. Clin. Cancer Res., 2006, 12, 5869-5878.
30. Getlik, M.; Grutter, C.; Simard, J. R.; Kluter, S.; Rabiller, M.; Rode, H. B.; Robubi, A.; Rauh, D. Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. J. Med. Chem., 2009, 52, 3915-3926.
31. Nautiyal, J.; Yu, Y.J.; Aboukameel, A.; Kanwar, S. S.; Das, J. K.; Du, J. H.; Patel, B. B.; Sarkar, F. H.; Rishi, A. K.; Mohammad, R. M.; Majumdar, A. P. N. ErbB-inhibitory protein: A modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells. Mol. Cancer Ther., 2010, 9, 1503-1514.
32. Johnson, F. M.; Bekele, B. N.; Feng, L.; Wistuba, I.; Tang, X. M.; Tran, H. T.; Erasmus, J. J.; Hwang, L. L.; Takebe, N.; Blumenschein, G. R.; Lippman, S. M.; Stewart, D. J. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol., 2010, 28, 4609-4615.
33. Shin, H. W.; Cho, C. H.; Kim, T. Y.; Park, J. W. Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1α synthesis in HT-29 colon cancer cells. Biochem. Biophys. Res. Comm., 2010, 398, 205-211.
34. Talks, K. L.; Turley, H.; Gatter, K. C.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. J.; Harris, A. L. The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol., 2000, 157, 411-421.
35. Bozec, A.; Sudaka, A.; Toussan, N.; Fischel, J.L.; Etienne-Grimaldi, M.C.; Milano, G. Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model. Ann. Onc., 2009, 20, 1703-1707.
36. Bauerschlag, D. O.; Schem, C.; Tiwari, S.; Egberts, J. H.; Weigel, M. T.; Kalthoff, H.; Jonat, W.; Maass, N.; Meinhold-Heerlein, I. Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice. Anticancer Res., 2010, 30, 3355-3360.
37. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Brueggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 2005, 7, 129-141.
38. Weisberg, E.; Manley, P.W.; Mestan, J.; Cowan-Jacob, S.; Ray, A.; Griffin, J. D. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. British J. Cancer, 2006, 94, 1765-1769.
39. Prenen, H.; Guetens, G.; de Boeck, G.; Debiec-Rychter, M.; Manley, P.; Schoffski, P.; van Oosterom, A. T.; de Bruijn, E. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacol., 2006, 77, 11-16.
40. Choi, H. G.; Ren, P. D.; Adrian, F.; Sun, F. X.; Lee, H. S.; Wang, X.; Ding, Q. A.; Zhang, G. B.; Xie, Y. P.; Zhang, J. M.; Liu, Y.; Tuntland, T.; Warmuth, M.; Manley, P. W.; Mestan, J.; Gray, N. S.; Sim, T. A type-II kinase inhibitor capable of inhibiting the T315I "Gatekeeper" mutant of Bcr-Abl. J. Med. Chem., 2010, 53, 5439-5448.
41. Wilhelm, S.; Chien, D. S. BAY 43-9006: preclinical data. Curr. Pharm. Des., 2002, 8, 2255-2257.
42. Wilhelm, S. M.; Carter, C.; Tang, L. Y.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X. M.; Vincent, P.; McHugh, M.; Cao, Y. C.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 2004, 64, 7099-7109.
43. Adnane, L.; Trail, P. A.; Taylor, I.; Wilhelm, S. M. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol., 2006, 407, 597-612.
44. Okamoto, I.; Miyazaki, M.; Morinaga, R; Kaneda, H.; Ueda, S.; Hasegawa, Y.; Satoh, T.; Kawada, A.; Fukuoka, M.; Fukino, K.; Tanigawa, T.; Nakagawa, K. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Invest. New Drugs, 2010, 28, 844-853.
45. Martinelli, E.; Troiani, T.; Morgillo, F.; Rodolico, G.; Vitagliano, D.; Morelli, M.P.; Tuccillo, C.; Vecchione, L.; Capasso, A.; Orditura, M.; De Vita, F.; Eckhardt, S.G.; Santoro, M.; Berrino, L.; Ciardiello, F. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin. Cancer Res., 2010, 16, 4990-5001.
46. Degen, A.; Satzger, I.; Voelker, B.; Kapp, A.; Hauschild, A.; Gutzmer, R. Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? Dermatology, 2010, 221, 193-196.
47. Hutson, T. E.; Bellmunt, J.; Porta, C.; Szczylik, C.; Staehler, M.; Nadel, A.; Anderson, S.; Bukowski, R.; Eisen, T.; Escudier, B. Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET. Eur. J. Cancer, 2010, 46, 2432-2440.
48. Bible, K. C.; Suman, V. J.; Molina, J. R.; Smallridge, R. C.; Maples, W. J.; Menefee, M. E.; Rubin, J.; Sideras, K.; Morris, J. C.; McIver, B.; Burton, J. K.; Webster, K. P.; Bieber, C.; Traynor, A. M.; Flynn, P. J.; Goh, B. C.; Tang, H.; Ivy, S. P.; Erlichman, C. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol., 2010, 11, 962-972.
49. Taylor, S. K.; Chia, S.; Dent, S.; Clemons, M.; Agulnik, M.; Grenci, P.; Wang, L. S.; Oza, A. M.; Ivy, P.; Pritchard, K. I.; Leighl, N. B. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: A trial of the Princess Margaret Hospital phase II consortium. Oncologist, 2010, 15, 810-818.
50. Monk, B. J.; Lopez, L. M.; Zarba, J. J.; Oaknin, A.; Tarpin, C.; Termrungruanglert, W.; Alber, J. A.; Ding, J.; Stutts, M. W.; Pandite, L. N. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J. Clin. Oncol., 2010, 28, 3562-3569.
51. Merritt, W. M.; Nick, A. M.; Carroll, A. R.; Lu, C. H.; Matsuo, K.; Dumble, M.; Jennings, N.; Zhang, S. Y.; Lin, Y. G.; Spannuth, W. A.; Kamat, A. A.; Stone, R. L.; Shahzad, M. M. K.; Coleman, R. L.; Kumar, R.; Sood, A. K. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol. Cancer Ther., 2010, 9, 985-995.
52. Hashimoto, K.; Man, S.; Xu, P.; Cruz-Munoz, W.; Tang, T.; Kumar, R.; Kerbel, R. S. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol. Cancer Ther., 2010, 9, 996-1006.
53. Nelson, M. H.; Dolder, C. R. Lapatinib: A novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann. Pharmacother., 2006, 40, 261-269.
54. Cameron, D.; Casey, M.; Oliva, C.; Newstat, B.; Imwalle, B.; Geyer, C.E. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: Final survival analysis of a phase III randomized trial. Oncologist, 2010, 15, 924-934.
55. Sherrill, B.; Amonkar, M. M.; Sherif, B.; Maltzman, J.; O'Rourke, L.; Johnston, S. Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist, 2010, 15, 944-953.
56. Kim, H. P.; Han, S. W.; Kim, S. H.; Im, S. A.; Oh, D. Y.; Bang, Y. J.; Kim, T. Y. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol. Cancer Ther., 2008, 7, 607-615.
57. Tanner, M.; Hollmén. M.; Junttila, T. T.; Kapanen, A. I.; Tommola, S.; Soini, Y.; Helin, H.; Salo, J.; Joensuu, H.; Sihvo, E.; Elenius, K.; Isola, J. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol., 2005, 16, 273-278.
58. Avizienyte, E.; Ward, R. A.; Garner, A. P. Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. Biochem. J., 2008, 415, 197-206.
59. Wang, S. E.; Narasanna, A.; Perez-Torres, M.; Xiang, B.; Wu, F. Y.; Yang, S.; Carpenter, G.; Gazdar, A. F.; Muthuswamy, S. K.; Arteaga, C. L. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell, 2006, 10, 25-38.
60. Tanizaki, J.; Okamoto, I.; Takezawa, K.; Tsukioka, S.; Uchida, J.; Kiniwa, M.; Fukuoka, M.; Nakagawa, K. Synergistic antitumor ef fect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. Mol. Cancer Ther., 2010, 9, 1198-1207.
61. Teng, W. C.; Oh, J. W.; New, L. S.; Wahlin, M. D.; Nelson, S. D.; Ho, H. K.; Chan, E. C. Y. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol. Pharmacol., 2010, 78, 693-703.
62. Motzer, R. J.; Escudier, B.; Oudard, S.; Hutson, T. E.; Porta, C.; Bracarda, S.; Grunwald, V.; Thompson, J. A.; Figlin, R. A.; Hollaender, N.; Kay, A.; Ravaud, A. Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer, 2010,116, 4256-4265.
63. Miyazawa, M.; Yasuda, M.; Fujita, M.; Kajiwara, H.; Hirabayashi, K.; Takekoshi, S.; Hirasawa, T.; Murakami, M.; Ogane, N.; Kiguchi, K.; Ishiwata, I.; Mikami, M.; Osamura, R.Y. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol. Int., 2009, 59, 19-27.
64. Cejka, D.; Preusser, M.; Fuereder, T.; Sieghart, W.; Werzowa, J.; Strommer, S.; Wacheck, V. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Res., 2008, 28(6A), 3801-3808.
65. Wang, L,; Shi, W. Y.; Wu, Z. Y.; Varna, M.; Wang, A. H.; Zhou, L.; Chen, L.; Shen, Z. X.; Lu, H.; Zhao, W. L.; Janin, A. Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma. J. Hematol. Oncol., 2010, 3
66. Smith, S.M.; van Besien, K.; Karrison, T.; Dancey, J.; McLaughlin, P.; Younes, A.; Smith, S.; Stiff, P.; Lester, E.; Modi, S.; Doyle, L. A.; Vokes, E. E. Pro, B. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J. Clin. Oncol., 2010, 28, 4740-4746.
67. Toppmeyer, D. L.; Goodin, S. Ixabepilone, a new treatment option for metastatic breast cancer. Am. J. Clin. Oncol.-CANC, 2010, 33, 516-521.
68. Egerton, N. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. Cancer Chemother. Pharmacol. 2010, 66, 1005-1012.
69. Muriel, C.; Esteban, E.; Corral, N.; Fonseca, P.J.; Luque, M.; Berros, J.; Fernández, Y.; Blay, P.; Fra, J.; Villanueva, N.; Sanmamed, M.; Pardo, P.; Izquierdo, M.; Vieitez, J.; Estrada, E.; Lacave, Á. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias. Clin. Translational Oncol., 2010, 12, 562-567.
70. Sosman, J.; Puzanov, I. Combination targeted therapy in advanced renal cell carcinoma. Cancer, 2009, 115(Suppl 10), 2368-2375.
71. Sun, M.; Lughezzani, G.; Perrotte, P.; Karakiewicz, P. I. Treatment of metastatic renal cell carcinoma. Nat. Rev. Urol., 2010, 7, 327-338.
72. Hainsworth, J. D.; Sosman, J. A.; Spigel, D. R.; Edwards, D. L.; Baughman, C.; Greco, A. Treatment of metastatic renal cell-carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol., 2005, 23, 7889-7896.
73. Hainsworth, J. D.; Spigel, D. R.; Sosman, J. A.; Burris, H. A.; Farley, C.; Cucullu, H.; Yost, K.; Hart, L. L.; Sylvester, L.; Waterhouse, D. M.; Greco, F. A. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin. Genitourin. Cancer, 2007, 5, 427-432.
74. Naumov, G. N.; Nilsson, M. B.; Cascone, T.; Briggs, A.; Straume, O.; Akslen, L. A.; Lifshits, E.; Byers, L. A.; Xu, L.; Wu, H. K.; Janne, P.; Kobayashi, S.; Halmos, B.; Tenen, D.; Tang, X. M.; Engelman, J.; Yeap, B.; Folkman, J.; Johnson, B. E.; Heymach, J. V. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin. Cancer Res., 2009, 15, 3484-3494.
75. Wells, S. A.; Gosnell, J. E.; Gagel, R. F.; Moley, J.; Pfister, D.; Sosa, J. A.; Skinner, M.; Krebs, A.; Vasselli, J.; Schlumberger, M. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid Cancer. J. Clin. Oncol., 2010, 28, 767-772.
76. Morabito, A.; Piccirollo, M. C.; Falasconi, F.; de Feo, G.; Giudice, A. D.; Bryce, J.; Di Maio, M.; de Maio, E.; Normanno, N.; Perrone, F. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: Current status and future directions. Oncologist, 2009, 14, 378-390.
77. Wedge, S. R.; Ogilvie, D. J.; Dukes, M.; Kendrew, J.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Valentine, P. J.; Curwen, J. O.; Musgrove, H. L.; Graham, G. A.; Hughes, G. D.; Thomas. A. P.; Stokes, E. S. E.; Curry, B.; Richmond, G. H. P.; Wadsworth, P. F.; Bigley, A. L.; Hennequin, L. F. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res., 2002, 62, 4645-4655.
78. Matsurnori, Y.; Yano, S.; Goto, H.; Nakataki, E.; Wedge, S. R.; Ryan, A. J.; Sone, S. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol. Res., 2006, 16(1), 15-26.
79. Ichihara, E.; Ohashi, K.; Takigawa, N.; Osawa, M.; Ogina, A.; Tanimoto, M.; Kiura, K. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. Cancer Res., 2009, 69, 5091-5098.
80. Natale, R. B.; Bodkin, D.; Govindan, R.; Sleckman, B. G.; Rizvi, N. A.; Capó, A.; Germonpré, P.; Eberhardt, W. E.E.; Stockman, P. K.; Kennedy, S. J.; Ranson, M. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a two-part, double-blind, randomized phase II study. J. Clin. Oncol., 2009, 27, 2523-2529.
81. Herbst, R. S.; Sun, Y.; Eberhardt, W. E. E.; Germonpré, P.; Saijo, N.; Zhou, C. C.; Wang, J.; Li, L. Y.; Kabbinavar, F.; Ichinose, Y.; Qin, S. K.; Zhang, L.; Biesma, B.; Heymach, J. V.; Langmuir, P.; Kennedy, S. J.; Tada, H.; Johnson, B. E. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial Lancet Oncol., 2010, 11, 619-626.
82. Yoshikawa, D.; Ojima, H.; Kokubu, A.; Ochiya, T.; Kasai, S.; Hirohashi, S.; Shibata, T. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Brit. J. Cancer, 2009, 100, 1257-1266.
83. Wedge, S. R.; Kendrew, J.; Hennequin, L. F.; Valentine, P. J.; Barry, S. T.; Brave, S. R.; Smith, N. R.; James, N. H.; Dukes, M.; Curwen, J. O.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Kilburn, L. L.; Barnett, S.; Richmond, G. H. P.; Wadsworth, P. F.; Walker, M.; Bigley, A. L.; Taylor, S. T.; Cooper, L.; Beck, S.; Jürgensmeier, J. M.; Ogilvie, D. J. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res., 2005, 65(10), 4389-4400.
84. Goss, G. D.; Arnold, A.; Shepherd, F. A.; Dediu, M.; Ciuleanu, T. E.; Fenton, D.; Zukin, M.; Walde, D.; Laberge, F.; Vincent, M. D.; Ellis, P. M.; Laurie, S. A.; Ding, K.; Frymire, E.; Gauthier, I.; Leighl, N. B.; Ho, C.; Noble, J.; Lee, C. W.; Seymour, L. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J. Clin. Oncol., 2010, 28, 49-55.
85. Matulonis, U. A.; Berlin, S.; Ivy, P.; Tyburski, K.; Krasner, C.; Zarwan, C.; Berkenblit, A.; Campos, S.; Horowitz, N.; Cannistra, S.A.; Lee, H.; Lee, J.; Roche, M.; Hill, M.; Whalen, C.; Sullivan, L.; Tran, C.; Humphreys, B. D.; Penson, R. T. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J. Clin. Oncol., 2009, 27, 5601-5606.
86. Fiedler, W.; Mesters, R.; Heuser, M.; Ehninger, G.; Berdel, W. E.; Zirrgiebel, U.; Robertson, J. D.; Puchalski, T. A.; Collins, B.; Jurgensmeier, J. M.; Serve, H. An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. Leukemia Res., 2010, 34, 196-202.
87. van Cruijsen, H.; Voest, E. E.; Punt, C. J.; Hoekman, K.; Witteveen, P. O.; Meijerink, M. R.; Puchalski, T. A.; Robertson, J.; Saunders, O.; Jurgensmeier, J. M.; van Herpen, C. M.; Giaccone, G. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumors. Eur. J. Cancer, 2010, 46, 901-911.
88. Coxon, A.; Bush, T.; Saffran, D.; Kaufman, S.; Belmontes, B.; Rex, K.; Hughes, P.; Caenepeel, S.; Rottman, J. B.; Tasker, A.; Patel, V.; Kendall, R.; Radinsky, R.; Polverino, A. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selec tive, oral iInhibitor of vascular endothelial growth factor, plateletderived growth factor, and Kit receptors. Clin. Cancer Res., 2009, 15, 110-118.
89. Caenepeel, S.; Renshaw-Gegg, L.; Baher, A.; Bush, T. L.; Baron, W.; Juan, T.; Manoukian, R.; Tasker, A. S.; Polverino, A.; Hughes, P. E. Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors. J. Exp. Clin. Cancer Res., 2010, 29, 96-96.
90. Amgen News Release, http://investors.amgen.com.
91. Bonner, J. A.; Harari, P. M.; Giralt, J.; Cohen, R. B.; Jones, C. U.; Sur, R. K.; Raben, D.; Baselga, J.; Spencer, S. A.; Zhu, J. M.; Youssoufian, H.; Rowinsky, E. K.; Ang, K. K. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol., 2010, 11, 21-28.
92. Kruser, T. J.; Wheeler, D. L.; Armstrong, E. A.; Iida, M.; Kozak, K. R.; van der Kogel, A. J.; Bussink, J.; Coxon, A.; Polverino, A.; Harari, P. M. Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Clin. Cancer Res., 2010, 16, 3639-3647.
93. Clinical trials dagtabase, http://clinicaltrials.gov.
94. Hu-Lowe, D. D.; Zou, H. Y.; Grazzini, M. L.; Hallin, M. E.; Wickman, G. R.; Amundson, K.; Chen, J. H.; Rewolinski, D. A.; Yamazaki, S.; Wu, E. Y.; McTigue, M. A.; Murray, B. W.; Kania, R. S.; O'Connor, P.; Shalinsky, D. R.; Bender, S. L. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res., 2008, 14, 7272-7283.
95. Rixe, O.; Bukowski, R. M.; Michaelson, M. D.; Wilding, G.; Hudes, G. R.; Bolte, O.; Motzer, R. J.; Bycott, P.; Liou, K. F.; Freddo, J.; Trask, P. C.; Kim, S.; Rini, B. I. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol., 2007, 8, 975-984.
96. Spano, J. P.; Chodkiewicz, C.; Maurel, J.; Wong, R.; Wasan, H.; Barone, C.; Letourneau, R.; Bajetta, E.; Pithavala, Y.; Bycott, P.; Trask, P.; Liau, K.; Ricart, A. D.; Kim, S.; Rixe, O. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet, 2008, 371, 2101-2108.
97. Cook, N.; Basu, B.; Biswas, S.; Kareclas, P.; Mann, C.; Palmer, C.; Thomas, A.; Nicholson, S.; Morgan, B.; Lomas, D.; Sirohi, B.; Mander, A.P.; Middleton, M.; Corrie, P. G. A phase 2 study of vatalanib in metastatic melanoma patients. Eur. J. Cancer, 2010, 46, 2671-2673.
98. Jaeger-Lansky, A.; Cejka, D.; Ying, L.; Preusser, M.; Hoeflmayer, D.; Fuereder, T.; Koehrer, S.; Wacheck, V. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo. Cancer Biol. Ther., 2010, 9, 919-927.
99. Joensuu, H.; De Braud, F.; Coco, P.; De Pas, T.; Putzu, C.; Spreafico, C.; Bono, P.; Bosselli, S.; Jalava, T.; Laurent, D.; Casali, P.G. Annal. Oncol., 2008, 19, 173-177.
100. Los, M.; Roodhart, J. M. L.; Voest, E. E. Target practice: Lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer Oncologist, 2007, 12, 443-450.
101. Paesler, J.; Gehrke, I.; Gandhirajan, R. K.; Filipovich, A.; Hertweck, M.; Erdfelder, F.; Uhrmacher, S.; Poll-Wolbeck, S. J.; Hallek, M.; Kreuzer, K. A. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Clin. Cancer Res., 2010, 16, 3390-3398.
102. Fury, M. G.; Zahalsky, A.; Wong, R.; Venkatraman, E.; Lis, E.; Hann, L.; Aliff, T.; Gerald, W.; Fleisher, M.; Pfister, D. G. A phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest. New Drug, 2007, 25, 165-172.
103. Overmoyer, B.; Fu, P.; Hoppel, C.; Radivoyevitch, T.; Shenk, R.; Persons, M.; Silverman, P.; Robertson, K.; Ziats, N. P.; Wasman, J. K.; Abdul-Karim, F. W.; Jesberger, J. A.; Duerk, J.; Hartman, P.; Hanks, S.; Lewin, J.; Dowlati, A.; McCrae, K.; Ivy, P.; Remick, S. C. Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. Clin. Cancer Res., 2007, 13, 5862-5868.
104. Kieran, M.W.; Supko, J. G.; Wallace, D.; Fruscio, R.; Poussaint, T. Y.; Phillips, P.; Pollack, I.; Packer, R.; Boyett, J. M.; Blaney, S.; Banerjee, A.; Geyer, R.; Friedman, H.; Goldman, S.; Kun, L. E.; MacDonald, T. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediat. Blood Cancer, 2009, 52, 169-176.
105. Katanasaka, Y.; Ida, T.; Asai, T.; Shimizu, K.; Koizumi, F.; Maeda, N.; Baba, K.; Oku, N. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1Hpyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416. Cancer Lett., 2008, 270, 260-268.
106. Hilberg, F.; Roth, G. J.; Krssak, M.; Kautschitsch, S.; Sommergruber, W.; Tontsch-Grunt, U.; Garin-Chesa, P.; Bader, G.; Zoephel, A.; Quant, J.; Heckel, A.; Rettig, W. J. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res., 2008, 68, 4774-4782.
107. Roth, G. J.; Heckel, A.; Colbatzky, F.; Handschuh, S.; Kley, J.; Lehmann-Lintz, T.; Lotz, R.; Tontsch-Grunt, U.; Walter, R.; Hilberg, F. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med. Chem., 2009, 52, 4466-4480.
108. Mross, K.; Stefanic, M.; Gmehling, D.; Frost, A.; Baas, F.; Unger, C.; Strecker, R.; Henning, J.; Gaschler-Markefski, B.; Stopfer, P.; de Rossi, L.; Kaiser, R. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin. Cancer Res., 2010, 16, 311-319.
109. Ellis, P. M.; Kaiser, R.; Zhao, Y. H.; Stopfer, P.; Gyorffy, S.; Hanna, N. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin. Cancer Res., 2010, 16, 2881-2889.
110. Okamoto, I.; Kaneda, H.; Satoh, T.; Okamoto, W.; Miyazaki, M.; Morinaga, R.; Ueda, S.; Terashima, M.; Tsuya, A.; Sarashina, A.; Konishi, K.; Arao, T.; Nishio, K.; Kaiser, R.; Nakagawa, K. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol. Cancer Ther., 2010, 9, 2825-2833.
111. Barbarroja, N.; Torres, L. A.; Rodriguez-Ariza, A.; Valverde-Estepa, A.; Lopez-Sanchez, L. M.; Ruiz-Limon, P.; Perez-Sanchez, C.; Carretero, R. M.; Velasco, F.; Lopez-Pedrera, C. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia. Exp. Hematol., 2010, 38, 641-652.
112. Juengel, E.; Engler, J.; Mickuckyte, A.; Jones, J.; Hudak, L.; Jonas, D.; Blaheta, R. A. Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro. BJU Int., 2010, 105, 549-557.
113. Okamoto, K.; Neureiter, D.; Alinger, B.; Meissnitzer, M.; Sass, G.; Schmitz, V.; Di Fazio, P.; Wissniowski, T.; Gahr, S.; Hohenstein, B.; Kaufmann, B.; Schlosser, A.; Haus, U.; Hahn, E.G.; Herold, C.; Ocker, M. The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice. Int. J. Oncol., 2008, 33, 733-742.
114. Schittenhelm, M. M.; Kampa, K. M.; Yee, K. W. H.; Heinrich, M. C. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle, 2009, 8, 2621-2630.
115. DeAngelo, D. J.; Stone, R. M.; Heaney, M. L.; Nimer, S. D.; Paquette, R. L.; Klisovic, R. B.; Caligiuri, M. A.; Cooper, M. R.; Lecerf, J. M.; Karol, M. D.; Sheng, S. H.; Holford, N.; T Curtin, P.; Druker, B. J.; Heinrich, M. C. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood, 2006, 108, 3674-3681.
116. Shankar, D. B.; Li, J. L.; Tapang, P.; McCall, J. O.; Pease, L. J.; Dai, Y.; Wei, R. Q.; Albert, D. H.; Bouska, J. J.; Osterling, D. J.; Guo, J.; Marcotte, P. A.; Johnson, E. F.; Soni, N.; Hartandi, K.; Michaelides, M. R.; Davidsen, S. K.; Priceman, S. J.; Chang, J. C.; Rhodes, K.; Shah, N.; Moore, T. B.; Sakamoto, K. M.; Glaser, K.B. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood, 2007, 109, 3400-3408.
117. Albert, D. H.; Tapang, P.; Magoc, T. J.; Pease, L. J.; Reuter, D. R.; Wei, R. Q.; Li, J. L.; Guo, J.; Bousquet, P. F.; Ghoreishi-Haack, N. S.; Wang, B.; Bukofzer, G. T.; Wang, Y. C.; Stavropoulos, J. A.; Hartandi, K.; Niquette, A. L.; Soni, N.; Johnson, E. F.; McCall, J. O.; Bouska, J. J.; Luo, Y.; Donawho, C.K.; Dai, Y. J.; Marcotte, P. A.; Glaser, K. B.; Michaelides, M. R.; Davidsen, S. K. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther., 2006, 5, 995-1006.
118. Dai, Y. J.; Hartandi, K.; Ji, Z. Q.; Ahmed, A. A.; Albert, D. H.; Bauch, J. L.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Glaser, K. B.; Harris, C. M.; Hickman, D.; Guo, J.; Li, J. L.; Marcotte, P. A.; Marsh, K. C.; Moskey, M. D.; Martin, R. L.; Olson, A. M.; Osterling, D. J.; Pease, L. J.; Soni, N. B.; Stewart, K. D.; Stoll, V. S.; Tapang, P.; Reuter, D. R.; Davidsen, S. K.; Michaelides, M. R. Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J. Med. Chem., 2007, 50, 1584-1597.
119. Wong, C. I.; Koh, T. S.; Soo, R.; Hartono, S.; Thng, C. H.; McKeegan, E.; Yong, W. P.; Chen, C. S.; Lee, S. C.; Wong, J.; Lim, R.; Sukri, N.; Lim, S. E.; Ong, A. B.; Steinberg, J.; Gupta, N.; Pradhan, R.; Humerickhouse, R.; Goh, B. C. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J. Clin. Oncol., 2009, 27, 4718-4726.
120. Renhowe, P. A.; Pecchi, S.; Shafer, C. M.; Machajewski, T. D.; Jazan, E. M.; Taylor, C.; Antonios-McCrea, W.; McBride, C. M.; Frazier, K.; Wiesmann, M.; Lapointe, G. R.; Feucht, P. H.; Warne, R. L.; Heise, C. C.; Menezes, D.; Aardalen, K.; Ye, H.; He, M.; Le, V.; Vora, J.; Jansen, J.M.; Wernette-Hammond, M. E.; Harris, A. L. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A novel class of receptor tyrosine kinase inhibitors. J. Med. Chem., 2009, 52, 278-292.
121. de Menezes, D. E. L.; Peng, J.; Garrett, E. N.; Louie, S. G.; Lee, S. H.; Wiesmann, M.; Tang, Y.; Shephard, L.; Goldbeck, C.; Oei, Y.; Ye, H.; Aukerman, S. L.; Heise, C. CHIR-258: A potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin. Cancer Res., 2005, 11, 5281-5291.
122. Sarker, D.; Molife, R.; Evans, T. R. J.; Hardie, M.; Marriott, C.; Butzberger-Zimmerli, P.; Morrison, R.; Fox, J. A.; Heise, C.; Louie, S.; Aziz, N.; Garzon, F.; Michelson, G.; Judson, I. R.; Jadayel, D.; Braendle, E.; de Bono, J. S. A Phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin. Cancer Res., 2008, 14, 2075-2081.
123. Strumberg, D.; Schultheis, B.; Adamietz, I. A.; Christensen, O.; Buechert, M.; Kraetzschmar, J.; Rajagopalan, P.; Ludwig, M.; Frost, A.; Steinbild, S.; Scheulen, M. E.; Mross, K. Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumors. Brit. J. Cancer, 2008, 99, 1579-1585.
124. Langenberg, M. H. G.; Witteveen, P. O.; Roodhart, J. M.; Verheul, H. M. W.; Mergui-Roelvink, M.; van der Sar, J.; Brendel, E.; Laferriere, N.; Schellens, J. H. M.; Voest, E. E. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. Clin. Cancer Res., 2010, 16, 2187-2197.
125. Ikuta, K.; Yano, S.; Trung, V. T.; Hanibuchi, M.; Goto, H.; Li, Q.; Wang, W.; Yamada, T.; Ogino, H.; Kakiuchi, S.; Uehara, H.; Sekido, Y.; Uenaka, T.; Nishioka, Y.; Sone, S. E7080, a multityrosine kinase inhibitor, suppresses the progression of malignant Pleural mesothelioma with different proangiogenic cytokine production profiles. Clin. Cancer Res., 2009, 15, 7229-7237.
126. Matsui, J.; Funahashi, Y.; Uenaka, T.; Watanabe, T.; Tsuruoka, A.; Asada, M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin. Cancer Res., 2008, 14, 5459-5465.
127. Naumova, E.; Ubezio, P.; Garofalo, A.; Borsotti, P.; Cassis, L.; Riccardi, E.; Scanziani, E.; Eccles, S. A.;, Bani, M. R.; Giavazzi, R. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin. Cancer Res., 2006, 12, 1839-1849.
128. Sessa, C.; Vigano, L.; Grasselli, G.; Trigo, J.; Marimon, I.; Llado, A.; Locatelli, A.; Ielmini, N.; Marsoni, S.; Gianni, L. Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. Eur. J. Cancer, 2006, 42, 171-178.
129. Qian, F.; Engst, S.; Yamaguchi, K.; Yu, P.W.; Won, K. A.; Mock, L.; Lou, T. Tan, J.; Li, C.; Tam, D.; Lougheed, J.; Yakes, F. M.; Bentzien, F.; Xu, W.; Zaks, T.; Wooster, R.; Greshock, J.; Joly, A. H. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res., 2009, 69, 8009-8016.
130. Bean, J.; Brennan, C.; Shih, J. Y.; Riely, G.; Viale, A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; Balak, M.; Chang, W.C.; Yu, C. J.; Gazdar, A.; Pass, H.; Rusch, V.; Gerald, W.; Huang, S. F.; Yang, P. C.; Miller, V.; Ladany, M.; Yang, C. H.; Pao, W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA, 2007, 104, 20932-20937.
131. Huynh, H.; Ngo, V. C.; Fargnoli, J.; Ayers, M.; Soo, K.C.; Koong, H. N.; Thng, C. H.; Ong, H. S.; Chung, A.; Chow, P.; Pollock, P.; Byron, S.; Tran, E. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer Res., 2008, 14, 6146-6153.
132. Cai, Z. W.; Zhang, Y.; Borzilleri, R. M.; Qian, L.; Barbosa, S.; Wei, D.; Zheng, X.; Wu, L.; Fan, J.; Shi, Z.; Wautlet, B. S.; Mortillo, S.; Jeyaseelan, R.; Kukral, D. W.; Kamath, A.; Marathe, P.; D'Arienzo, C.; Derbin, G.; Barrish, J. C.; Robl, J. A.; Hunt, J. T.; Lombardo, L. J.; Fargnoli, J.; Bhide, R. S. Discovery of brivanib alaninate (S)-(R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J. Med. Chem., 2008, 51, 1976-1980.
133. Marathe, P. H.; Kamath, A. V.; Zhang, Y.; D'Arienzo, C.; Bhide, R.; Fargnoli, J. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemther. Pharmacol., 2009, 65, 55-66.
134. Campas, C.; Bolos, J.; Castaner, R. Tivozanib. Drugs Fut. 2009, 34, 793-796.
135. O'Hare, T.; Shakespeare, W. C.; Zhu, X. T.; Eide, C. A.; Rivera, V. M.; Wang, F.; Adrian, L. T.; Zhou, T. J.; Huang, W. S.; Xu, Q. H.; Metcalf, C. A.; Tyner, J. W.; Loriaux, M. M.; Corbin, A. S.; Wardwell, S.; Ning, Y. Y.; Keats, J. A.; Wang, Y. H.; Sundaramoorthi, R.; Thomas, M.; Zhou, D.; Snodgrass, J.; Commodore, L.; Sawyer, T. K.; Dalgarno, D. C.; Deininger, M. W. N.; Druker, B. J.; Clackson, T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16, 401-412.
136. Huang, W. S.; Metcalf C. A.; Sundaramoorthi, R.; Wang, Y. H.; Zou, D.; Thomas, R. M.; Zhu, X. T.; Cai, L. S.; Wen, D.; Liu, S. Y.; Romero, J.; Qi, J. W.; Chen, I.; Banda, G.; Lentini, S. P.; Das, S.; Xu, Q. H.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y. Y.; Snodgrass, J. T.; Broudy, M. I.; Russian, K.; Zhou, T. J.; Commodore, L.; Narasimhan, N. I.; Mohemmad, Q. K.; Iuliucci, J.; Rivera, V. M.; Dalgarno, D. C.; Sawyer, T. K.; Clackson, T.; Shakespeare, W. C. Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCRABL) kinase including the T315I gatekeeper mutant. J. Med. Chem., 2010, 53, 4701-4719.
137. Baker, C. H.; Solorzano, C. C.; Fidler, I. J. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res., 2002, 62, 1996-2003.
138. Kantarjian, H. M.; Giles, F.; Gattermann, N.; Bhalla, K.; Alimena, G.; Palandri, F.; Ossenkoppele, G. J.; Nicolini, F. E.; O'Brien, S. G.; Litzow, M.; Bhatia, R.; Cervantes, F.; Haque, A.; Shou, Y.; Resta, D. J.; Weitzman, A.; Hochhaus, A.; le Coutre, P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood, 2007, 110, 3540-3546.
139. Shah, N. P.; Skaggs, B. J.; Branford, S.; Hughes, T. P.; Nicoll, J. M.; Paquette, R. L.; Sawyers, C. L. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest., 2007, 117, 2562-2569.
140. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res., 2004, 64, 6652-6659.